The publication of positive results from the Phase 3 RAPID clinical trial of Etripamil nasal spray in The Lancet demonstrates the efficacy and safety of the drug in patients with PSVT. This news is likely to increase investor interest in Milestone Pharmaceuticals, as it indicates progress in the development of the drug and its potential for approval and commercialization. The positive results may lead to a short-term increase in the stock price of MIST.